查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1880519

2032年腎臟病治療市場預測：按疾病類型、藥物類別、給藥途徑、通路、最終用戶和地區分類的全球分析

Preeclampsia Drugs Market Forecasts to 2032 - Global Analysis By Condition Type (Mild Preeclampsia and Severe Preeclampsia), Drug Class, Route of Administration, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的一項研究，預計到 2025 年，全球腎臟病治療市場價值將達到 12.5 億美元，到 2032 年將達到 27.7 億美元，在預測期內的複合年成長率為 12.0%。

妊娠毒血症）和皮質類固醇（用於促進胎兒肺部成熟）。雖然這些藥物不能治癒妊娠毒血症，治療方法它們可以幫助控制嚴重的症狀，並穩定病情，直到分娩成為最安全的選擇。

根據美國心臟協會的記錄，妊娠毒血症影響約 5-7% 的孕婦，是發病率和死亡率最高的疾病。在全球範圍內，該疾病每年導致超過 7 萬名孕產婦死亡和超過 50 萬名胎兒死亡。

風險因素增加

隨著診斷意識的提高，越來越多的病例在早期階段被發現，增加了對有效藥物治療的需求。醫療系統正在採用先進的篩檢工具，例如生物標記檢測和基於人工智慧的風險預測模型。這些技術幫助臨床醫生更早發現孕產婦併發症，增加了預防性和治療性藥物的使用。標靶治療和個人化治療通訊協定的創新進一步推動了市場擴張。隨著生活方式相關風​​險因素在全球範圍內日益受到關注，對可靠的妊娠毒血症管理解決方案的需求持續成長。

缺乏標準化的治療通訊協定

不同地區診斷標準的差異導致治療方法不一致，並造成干涉延誤。新興的數位健康工具和臨床決策支援系統旨在簡化通訊協定，但尚未普遍應用。小規模醫療機構面臨訓練不足和缺乏先進孕產婦監測技術等問題。這種不一致延緩了新藥製劑的上市，並阻礙了臨床試驗的標準化。因此，缺乏明確的指南持續限制市場成長。

預防療法的開發

製藥公司正投資研發低劑量阿斯匹靈製劑、抗氧化劑和新興生物製劑，以預防疾病的發生。基因組學和預測分析技術的進步使得在懷孕早期識別高風險孕婦成為可能。這些進步使得利用穿戴式孕婦健康追蹤器和人工智慧預測平台進行個人化預防性治療成為可能。目前，一些針對內皮功能障礙和胎盤異常的極具前景的在研藥物正在進行臨床試驗。隨著預防性治療在全球日益受到關注，市場有望迎來顯著成長。

來自非藥物療法的競爭壓力

非藥物療法，例如飲食調整、生活方式介入和數位化產前監測工具，正逐漸成為藥物治療的替代方案。穿戴式裝置和遠端醫療平台無需藥物即可實現持續的風險評估。隨著患者偏好轉向非侵入性治療方案，製藥公司面臨激烈的競爭壓力。減少對藥物治療依賴的綜合產前護理模式正變得越來越普遍，為了應對這一趨勢，各公司正在將數位化工具與藥物治療相結合，以保持市場競爭力。

新冠疫情的影響：

新冠疫情擾亂了產前保健，導致妊娠毒血症症診斷延遲，病情加重。封鎖措施影響了藥品供應鏈，造成生產延誤，並導致產前藥物暫時短缺。然而，這種情況加速了遠距產前保健所需的數位監測工具的普及。遠端醫療平台和連網血壓監測設備已成為產前保健流程中不可或缺的一部分。疫情後，醫療保健產業正優先建構具有韌性的供應鏈網路和混合式產前保健模式。

預計在預測期內，重度妊娠毒血症症細分市場將佔據最大的市場佔有率。

由於住院率上升和硫酸鎂降血壓療法的使用增加，預計在預測期內，重妊娠毒血症症細分市場將佔據最大的市場佔有率。加護治療醫學的進步和病患監測技術的改進正在推動該細分市場的擴張。人工智慧驅動的胎兒健康評估工具的日益普及正在提升重症病例的決策水準。針對內皮修復和胎盤功能障礙的新型候選藥物的出現進一步推動了該細分市場的成長。臨床指引也更加重視重症病例的積極治療，導致藥物消費量增加。

預計在預測期內，專科診所細分市場將呈現最高的複合年成長率。

預計在預測期內，專科診所領域將實現最高成長率，這主要得益於母胎醫學服務覆蓋範圍的擴大。這些診所正在迅速採用先進的診斷工具，例如多普勒成像、生物感測器和預測分析平台。高危險妊娠計畫的擴展也促進了標靶藥物治療的使用。遠距醫療和遠距胎兒監護的整合正在提升專科醫療機構的護理連續性。專科診所專注於個人化孕產婦護理，並正大力投資創新治療方法和數位化工具。

佔比最大的地區：

由於出生率上升和妊娠併發症增多，預計亞太地區將在預測期內佔據最大的市場佔有率。中國、印度、日本和東南亞各國政府正在加大投入，以實現孕產婦保健系統的現代化。包括生物標記篩檢和基於人工智慧的孕產婦監測在內的先進診斷技術在該地區的應用正在加速。製藥公司正透過合作、臨床試驗和本地生產設施擴大其市場佔有率。不斷加強的宣傳活動正在促進妊娠毒血症的早期診斷和治療。

預計年複合成長率最高的地區：

在預測期內，北美預計將實現最高的複合年成長率，這主要得益於其強大的技術領先地位和先進孕產婦護理解決方案的快速普及。該地區受益於以生物製藥、標靶治療和個人化醫療為重點的強勁研發投入。醫院和診所正擴大採用物聯網賦能的孕產婦監測設備和人工智慧驅動的診斷工具。監管機構正致力於簡化創新孕產婦藥物的核准流程。美國和加拿大民眾對高風險懷孕的日益關注，正在推動對先進治療方法的需求。

免費客製化服務：

購買此報告的客戶可以選擇以下免費自訂選項之一：

  • 公司概況
    • 對其他市場公司（最多 3 家公司）進行全面分析
    • 主要企業SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶要求，對主要國家的市場規模進行估算和預測，併計算複合年成長率（註：可行性需確認）。
  • 競爭基準化分析
    • 根據主要企業的產品系列、地理覆蓋範圍和策略聯盟基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 數據分析
    • 數據檢驗
    • 研究途徑
  • 研究材料
    • 原始研究資料
    • 次級研究資訊來源
    • 先決條件

第3章 市場趨勢分析

  • 介紹
  • 促進要素
  • 抑制因素
  • 機會
  • 威脅
  • 終端用戶分析
  • 新興市場
  • 新冠疫情的影響

第4章 波特五力分析

  • 供應商的議價能力
  • 買方的議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭對手之間的競爭

5. 全球腎臟病治療市場（依病症類型分類）

  • 介紹
  • 輕度子癇前症
  • 重度子癇前症

6. 全球腎臟病藥物市場（依藥物類別分類）

  • 介紹
  • 抗高血壓藥物
  • 抗驚厥藥
  • 皮質類固醇
  • 其他藥物

7. 全球腎臟病藥物市場（依給藥途徑分類）

  • 介紹
  • 口服
  • 腸外

8. 全球腎臟病藥物市場（依通路分類）

  • 介紹
  • 醫院藥房
  • 零售藥房
  • 網路藥房

9. 全球腎臟病藥物市場（依最終用戶分類）

  • 介紹
  • 醫院
  • 診斷中心
  • 專科診所
  • 其他最終用戶

10. 全球腎臟病藥物市場（按地區分類）

  • 介紹
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 亞太其他地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 其他南美洲
  • 中東和非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲地區

第11章 重大進展

  • 協議、夥伴關係、合作和合資企業
  • 收購與併購
  • 新產品上市
  • 業務拓展
  • 其他關鍵策略

第12章：企業概況

  • Thermo Fisher Scientific Inc.
  • AbbVie Inc.
  • Baxter International Inc.
  • Johnson & Johnson
  • Bayer AG
  • AstraZeneca plc
  • Merck & Co., Inc.
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd.
  • Novartis AG
  • Pfizer Inc.
  • Eli Lilly and Company
  • GlaxoSmithKline plc
  • Teva Pharmaceutical Industries Ltd.
  • Takeda Pharmaceutical Company Limited
Product Code: SMRC32555

According to Stratistics MRC, the Global Preeclampsia Drugs Market is accounted for $1.25 billion in 2025 and is expected to reach $2.77 billion by 2032 growing at a CAGR of 12.0% during the forecast period. Preeclampsia drugs refer to medicines designed to control and treat preeclampsia, a condition in pregnancy marked by elevated blood pressure and potential organ damage. These treatments regulate blood pressure, lower seizure risk, and protect maternal and fetal health. Key options include blood-pressure-lowering drugs, magnesium sulfate for seizure prevention, and corticosteroids to enhance fetal lung maturity. Although they cannot eliminate preeclampsia, these medications help manage critical symptoms and maintain stability until delivery becomes the safest option.

According to the records of American Heart Association, Inc., the greatest morbidity and mortality, preeclampsia affects around 5% to 7% of all pregnant women; though, it is responsible for over 70, 000 maternal deaths and 500,000 fetal deaths worldwide each year.

Market Dynamics:

Driver:

Increasing prevalence of risk factors

As diagnostic awareness grows, more cases are being identified early, increasing the need for effective pharmacological interventions. Healthcare systems are adopting advanced screening tools such as biomarker-based tests and AI-enabled risk prediction models. These technologies are helping clinicians detect maternal complications sooner, driving the uptake of preventive and therapeutic drugs. Innovations in targeted therapies and personalized treatment protocols are further accelerating market expansion. With lifestyle-related risk factors intensifying globally, demand for reliable preeclampsia management solutions continues to grow.

Restraint:

Lack of standardized treatment protocols

Variability in diagnostic criteria across regions leads to inconsistent therapeutic approaches and delayed intervention. Emerging digital health tools and clinical decision-support systems aim to streamline protocols but are still not uniformly adopted. Smaller healthcare facilities struggle with limited training and access to advanced maternal monitoring technologies. This inconsistency slows the adoption of new drug formulations and hinders clinical trial standardization. As a result, the lack of clear guidelines continues to restrain market growth despite ongoing research.

Opportunity:

Development of preventive therapies

Pharmaceutical companies are investing in low-dose aspirin formulations, antioxidants, and emerging biologics designed to reduce disease onset. Advances in genomics and predictive analytics are helping identify high-risk patients earlier in pregnancy. These developments are enabling personalized preventive regimens supported by wearable maternal health trackers and AI-based prediction platforms. Several promising pipeline drugs are undergoing trials that target endothelial dysfunction and placental abnormalities. As preventive therapy gains global traction, the market is poised for significant expansion.

Threat:

Competitive pressure from non-pharmacological interventions

Non-drug approaches such as dietary modification, lifestyle programs, and digital maternal monitoring tools are increasingly offering alternatives to pharmacological treatment. Wearable devices and telehealth platforms are enabling continuous risk assessment without medication. As patient preference shifts toward non-invasive options, drug manufacturers face heightened competitive pressure. Integrative maternal care models are becoming prevalent, reducing reliance on pharmacotherapy alone. These trends are prompting companies to integrate digital tools with drug therapies to maintain market relevance.

Covid-19 Impact:

The Covid-19 pandemic disrupted prenatal care, leading to delayed diagnosis and increased severity of preeclampsia cases. Lockdowns affected drug supply chains and slowed manufacturing, causing temporary shortages of maternal medications. However, the situation accelerated adoption of digital monitoring tools, enabling remote prenatal assessments. Telemedicine platforms and connected blood-pressure monitoring devices became integral to maternal care workflows. Post-pandemic, healthcare systems are prioritizing resilient supply networks and hybrid maternal care models.

The severe preeclampsia segment is expected to be the largest during the forecast period

The severe preeclampsia segment is expected to account for the largest market share during the forecast period, due to rising hospitalization rates and increasing use of magnesium sulfate and antihypertensive therapies. Advancements in critical-care pharmacology and improved inpatient monitoring technologies are supporting this segment's expansion. The growing availability of AI-enabled fetal health assessment tools is enhancing decision-making in severe cases. Emerging drug candidates targeting endothelial repair and placental dysfunction are further strengthening segment growth. Clinical guidelines also prioritize aggressive management of severe cases, increasing drug consumption.

The specialty clinics segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the specialty clinics segment is predicted to witness the highest growth rate, due to expanding access to maternal-fetal medicine services. These clinics are rapidly adopting advanced diagnostic tools such as Doppler imaging, bio-sensors, and predictive analytics platforms. Growth in high-risk pregnancy programs is increasing the use of targeted drug regimens. The integration of tele-consultation and remote fetal monitoring is enhancing treatment continuity within specialty settings. With a focus on personalized maternal care, specialty clinics are investing in innovative therapeutics and digital tools.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share, due to rising birth rates and increasing prevalence of pregnancy-related complications. Governments across China, India, Japan, and Southeast Asia are investing in modernizing maternal healthcare systems. Adoption of advanced diagnostic technologies, including biomarker screening and AI-based maternal monitoring, is accelerating in the region. Pharmaceutical companies are expanding their presence through partnerships, clinical trials, and regional production facilities. Growing awareness campaigns are encouraging early diagnosis and treatment of preeclampsia.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to strong technological leadership and rapid adoption of advanced maternal care solutions. The region benefits from robust R&D investments focusing on biologics, targeted therapies, and personalized medicine. Hospitals and clinics are integrating IoT-enabled maternal monitoring devices and AI-powered diagnostic tools. Regulatory agencies are working toward streamlined approval pathways for innovative maternal drugs. Rising awareness of high-risk pregnancies in the U.S. and Canada is fueling demand for advanced treatments.

Key players in the market

Some of the key players in Preeclampsia Drugs Market include Thermo Fi, AbbVie Inc., Baxter International, Johnson & Johnson, Bayer AG, AstraZeneca, Merck & Co., Sanofi S.A., F. Hoffmann-La Roche, Novartis AG, Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline, Teva Pharmaceuticals, Takeda Pharmaceuticals.

Key Developments:

In November 2025, Pfizer Inc. announced the completion of its acquisition of Metsera, Inc., a clinical-stage biopharmaceutical company accelerating the next generation of medicines for obesity and cardiometabolic diseases. This strategic milestone represents more than a transaction it's a deliberate investment in the future of medicine.

In October 2025, Thermo Fisher Scientific announced a new research and development (R&D) partnership with the AstraZeneca BioVentureHub in Gothenburg, Sweden. The partnership aims to leverage the combined expertise of Thermo Fisher and AstraZeneca to drive innovation and strengthen the life science ecosystem.

Condition Types Covered:

  • Mild Preeclampsia
  • Severe Preeclampsia

Drug Classes Covered:

  • Antihypertensives
  • Anticonvulsants
  • Corticosteroids
  • Other Therapies

Route of Administrations Covered:

  • Oral
  • Parenteral

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

End Users Covered:

  • Hospitals
  • Diagnostic Centers
  • Specialty Clinics
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Preeclampsia Drugs Market, By Condition Type

  • 5.1 Introduction
  • 5.2 Mild Preeclampsia
  • 5.3 Severe Preeclampsia

6 Global Preeclampsia Drugs Market, By Drug Class

  • 6.1 Introduction
  • 6.2 Antihypertensives
  • 6.3 Anticonvulsants
  • 6.4 Corticosteroids
  • 6.5 Other Therapies

7 Global Preeclampsia Drugs Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Parenteral

8 Global Preeclampsia Drugs Market, By Distribution Channel

  • 8.1 Introduction
  • 8.2 Hospital Pharmacies
  • 8.3 Retail Pharmacies
  • 8.4 Online Pharmacies

9 Global Preeclampsia Drugs Market, By End User

  • 9.1 Introduction
  • 9.2 Hospitals
  • 9.3 Diagnostic Centers
  • 9.4 Specialty Clinics
  • 9.5 Other End Users

10 Global Preeclampsia Drugs Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Thermo Fisher Scientific Inc.
  • 12.2 AbbVie Inc.
  • 12.3 Baxter International Inc.
  • 12.4 Johnson & Johnson
  • 12.5 Bayer AG
  • 12.6 AstraZeneca plc
  • 12.7 Merck & Co., Inc.
  • 12.8 Sanofi S.A.
  • 12.9 F. Hoffmann-La Roche Ltd.
  • 12.10 Novartis AG
  • 12.11 Pfizer Inc.
  • 12.12 Eli Lilly and Company
  • 12.13 GlaxoSmithKline plc
  • 12.14 Teva Pharmaceutical Industries Ltd.
  • 12.15 Takeda Pharmaceutical Company Limited

List of Tables

  • Table 1 Global Preeclampsia Drugs Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Preeclampsia Drugs Market Outlook, By Condition Type (2024-2032) ($MN)
  • Table 3 Global Preeclampsia Drugs Market Outlook, By Mild Preeclampsia (2024-2032) ($MN)
  • Table 4 Global Preeclampsia Drugs Market Outlook, By Severe Preeclampsia (2024-2032) ($MN)
  • Table 5 Global Preeclampsia Drugs Market Outlook, By Drug Class (2024-2032) ($MN)
  • Table 6 Global Preeclampsia Drugs Market Outlook, By Antihypertensives (2024-2032) ($MN)
  • Table 7 Global Preeclampsia Drugs Market Outlook, By Anticonvulsants (2024-2032) ($MN)
  • Table 8 Global Preeclampsia Drugs Market Outlook, By Corticosteroids (2024-2032) ($MN)
  • Table 9 Global Preeclampsia Drugs Market Outlook, By Other Therapies (2024-2032) ($MN)
  • Table 10 Global Preeclampsia Drugs Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 11 Global Preeclampsia Drugs Market Outlook, By Oral (2024-2032) ($MN)
  • Table 12 Global Preeclampsia Drugs Market Outlook, By Parenteral (2024-2032) ($MN)
  • Table 13 Global Preeclampsia Drugs Market Outlook, By Distribution Channel (2024-2032) ($MN)
  • Table 14 Global Preeclampsia Drugs Market Outlook, By Hospital Pharmacies (2024-2032) ($MN)
  • Table 15 Global Preeclampsia Drugs Market Outlook, By Retail Pharmacies (2024-2032) ($MN)
  • Table 16 Global Preeclampsia Drugs Market Outlook, By Online Pharmacies (2024-2032) ($MN)
  • Table 17 Global Preeclampsia Drugs Market Outlook, By End User (2024-2032) ($MN)
  • Table 18 Global Preeclampsia Drugs Market Outlook, By Hospitals (2024-2032) ($MN)
  • Table 19 Global Preeclampsia Drugs Market Outlook, By Diagnostic Centers (2024-2032) ($MN)
  • Table 20 Global Preeclampsia Drugs Market Outlook, By Specialty Clinics (2024-2032) ($MN)
  • Table 21 Global Preeclampsia Drugs Market Outlook, By Other End Users (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.